|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||2.27 - 2.40|
|52 Week Range||2.08 - 4.29|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 9, 2018 - May 14, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||8.00|
VolitionRx Limited (AMEX:VNRX) is a small-cap stock with a market capitalization of US$71.75M. While investors primarily focus on the growth potential and competitive landscape of the small-cap companies, they endRead More...
NEW YORK, NY / ACCESSWIRE / March 20, 2018 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has issued ...
Stock Monitor: VolitionRx Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 15, 2018 / Active-Investors.com has just released a free research report on OpGen, Inc. (NASDAQ: OPGN ). If you want access ...
ISNES, Belgium, March 13, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national life sciences company focused on developing simple, easy to use, cost effective blood tests designed to help diagnose a range of cancers, announced today the closing of its previously announced underwritten public offering of 3,500,000 shares of common stock at a public offering price of $2.40 per share for gross proceeds of $8.4 million, before deducting underwriting discounts, commissions and estimated offering expenses payable by Volition. All of the shares of common stock sold in the offering were offered by Volition. Volition intends to use the net proceeds of the offering for continued product development, clinical studies, product commercialization, working capital, and other general corporate purposes.
ISNES, Belgium , March 9, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national life sciences company focused on developing simple, easy to use, cost effective ...
Oppenheimer & Co. Inc. is acting as the sole book-running manager for the proposed offering. National Securities Corporation, a wholly owned subsidiary of National Holdings Corporation (NHLD), is acting as a co-manager in connection with the offering. Volition intends to use the net proceeds of the offering for continued product development, clinical studies, product commercialization, working capital, and other general corporate purposes.
ISNES, Belgium, March 7, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that it has further strengthened its Scientific Advisory Board with the addition of Dr. Lee-Jen Wei, a professor of Biostatistics at Harvard University. Prof. Wei's main area of research is developing statistical methods for the design and analysis of clinical trials. Prof. Wei has developed numerous novel statistical methods used widely and is the author of more than 140 peer-reviewed publications.
By Brian Marckx, CFA NYSE:VNRX VolitionRx (NYSE:VNRX) reported Q4 results and provided a business update. Relative to the financials, results continue to come in well within our expectations with Q4 operating ...
VolitionRx Limited’s (AMEX:VNRX): VolitionRx Limited, a life sciences company, focuses on developing blood-based tests to diagnose a range of cancers. The US$84.33M market-cap posted a loss in its most recentRead More...
ISNES, Belgium, March 1, 2018 /PRNewswire/ -- VolitionRX Limited (NYSE AMERICAN: VNRX) ("Volition") today announced financial results for the full fiscal year ended December 31, 2017. Cameron Reynolds, Chief Executive Officer of Volition, upon releasing these results commented, "I could not be more proud of our dedicated team at Volition. During 2017, we, together with our collaborators, have made strong progress. After seven years of hard work, earlier this week we were excited to announce excellent early detection interim results from our ongoing front-line screening trial for colorectal cancer.
Conference call to take place Friday, March 2, 2018 at 8:30 am Eastern time ISNES, Belgium , Feb. 28, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE American: VNRX) today announced it will host a conference ...
This ongoing study is being carried out in collaboration with Hvidovre Hospital, University of Copenhagen, Denmark and involves 680 subjects from the Danish National CRC Screening Program. The interim results demonstrated that a small panel of three ELISA assays, when considered with the subjects' ages and smoking histories, produced an area under the curve (AUC) of 83% and was able to detect 80% of Stage I CRC cases and 66% of High-Risk Adenomas (HRA) at 78% specificity, respectively.
ISNES, Belgium, Feb. 5, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced the successful conclusion to the Logistics and Pathway Design Study conducted by Hvidovre Hospital and The Danish Research Group. The study was established to answer the very practical, logistical questions of how a triage blood test could fit into the current Danish screening program for colorectal cancer ("CRC"). The study showed that it was indeed possible to collect, process, gather and ship the blood test from all five participating hospitals to a central laboratory within 24 hours. Furthermore, analysis from the central laboratory was shown to provide the needed data in due time (in accordance with current Danish Legislation) to decide whether or not to perform a colonoscopy.
ISNES, Belgium, Jan. 3, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today released an important letter from Group CEO, Cameron Reynolds updating the company's shareholders. In the letter, Mr. Reynolds outlines several significant accomplishments to date and highlights the fact that the company believes that it is close to achieving a key clinical milestone with the completion of a 680-subject trial for the Nu.QTM Frontline Asymptomatic Colorectal Cancer Screening Test. Volition expects to report the results from this study in early February.
ISNES, Belgium , Dec. 5, 2017 /PRNewswire/ -- VolitionRx Limited (NYSE American: VNRX) today announced that its Executive Vice President, Scott Powell , is scheduled to attend two conferences in December. ...
By Brian Marckx, CFA NYSE:VNRX Q3 Results / Operational and Business Update: VolitionRx (NYSE:VNRX) reported Q3 results and provided a business update. Relative to the financials, results were very much ...
ISNES, Belgium, Nov. 10, 2017 /PRNewswire/ -- Singapore Volition Pte. Ltd, a wholly-owned subsidiary of VolitionRx Limited (NYSE American: VNRX) ("Volition"), has entered into a Memorandum of Understanding ("MOU") with the National Taiwan University ("NTU") to conduct two large colorectal cancer (CRC) research studies across the Asia Pacific Region, totaling approximately 7,000 patient samples. "The signing of this MOU is a good start for Volition in the Asia Pacific Region" commented Dr. Jasmine Kway, Volition's Vice President of Asia. "We are fortunate and delighted to be working with a renowned institution and Professor Han-Mo Chiu, a prominent thought leader. The first trial will be a large scale multi-country, multi-center and multi-ethnic study in the Asia Pacific Region, including 5,000 asymptomatic colorectal cancer screening subjects.
NEW YORK, NY / ACCESSWIRE / November 10, 2017 / Volitionrx Limited (NYSE: VNRX ) will be discussing their earnings results in their Q3 Earnings Call to be held on Friday, November 10, 2017 at 8:30 AM Eastern ...
Investors are always looking for growth in small-cap stocks like VolitionRx Limited (AMEX:VNRX), with a market cap of USD $78.23M. However, an important fact which most ignore is: how financiallyRead More...
On a per-share basis, the Singapore-based company said it had a loss of 15 cents. In the final minutes of trading on Thursday, the company's shares hit $3.12. A year ago, they were trading at $4.40. _____ ...
ISNES, Belgium, Nov. 9, 2017 /PRNewswire/ -- VolitionRx Limited (NYSE American: VNRX) today announced financial results and a business update for the third quarter ended September 30, 2017. Volition management will host a conference call tomorrow, November 10, at 8:30 a.m. U.S. Eastern Time to discuss these results. Mr. Cameron Reynolds, President and Chief Executive Officer of Volition, said, "We have made fantastic progress this quarter, moving our clinical product development strongly forward in Asia, Europe and the U.S, and broadening our potential revenue base with our recently announced research kit sales.
ISNES, Belgium, Sept. 22, 2017 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced its strategy for a new range of Clinical Research Use Only (RUO) kits based on its proprietary Nucleosomics™ technology and the receipt of an order of RUO kits from a large multinational pharmaceutical company. Chief Executive Officer of Volition, Cameron Reynolds, commented, "This is a very important milestone for Volition as it represents our first revenue from the Nu.Q™ platform. The RUO kits could be used to develop a companion diagnostic to a pharmaceutical company's therapeutic product, so could represent an additional potential revenue stream beyond the commercialization of our blood-based cancer tests on the same platform of assays.
ISNES, Belgium, Sept. 21, 2017 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that it has been awarded a loan and a non-repayable grant totaling $1.5 million from SOFINEX and the Walloon Region, Belgium. Dr. Gaetan Michel, Chief Executive Officer of Volition's subsidiary, Belgian Volition SPRL, commented, "We are delighted with the financial support that we continue to receive from our local agencies SOFINEX and Namur Invest, as well as the Walloon Region, Belgium.
ISNES, Belgium, Sept. 19, 2017 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced its colorectal cancer (CRC) strategy for Europe. As part of its strategy, Volition plans to select a frontline panel to be validated in two large trials (4,300 and 10,000 sample), followed by CE marking, with a goal to launch a European frontline CRC screening product in 2018. Chief Executive Officer of Volition, Cameron Reynolds, commented, "We believe that the market for the frontline screening test represents the largest near-term opportunity for Volition, as there are 150 million Europeans of screening age. "We are making significant progress with our frontline CRC screening test," said Dr. Gaetan Michel, Chief Executive Officer of Belgian Volition.
Volition's Vice President of Asia, Dr. Jasmine Kway, commented, "Asia is a very important market for Volition and we have made significant progress in the region since January of this year. There is a growing aging population in many countries in Asia, with more than 40% of worldwide colorectal cancers occurring there. Volition has been developing its position in Asia since the beginning of 2017 and has generated encouraging responses from key opinion leaders (KOLs) in the region.